FDA RMAT status puts Rznomics’ RNA editing platform under a brighter clinical spotlight
RNA editing just gained a liver cancer spotlight. Rznomics must now prove RZ-001 can turn early response signals into durable clinical value.
Can Rznomics turn RZ-001 into a breakthrough therapy for hepatocellular carcinoma?
Rznomics reported interim RZ-001 liver cancer data at AACR 2026. Read why the efficacy and safety signals could matter for hepatocellular carcinoma.